Amplification of anticancer efficacy by co-delivery of doxorubicin and lonidamine with extracellular vesicles

Li, Huizhen; Xu, Wenrong; Li, Fang; Zeng, Ru; Zhang, Xiuming; Wang, Tonghua; Zhao, Shaojun; Weng, Jian; Zhu, Li; Sun, Liping

doi:10.1080/10717544.2021.2023697

Cited by 31 publications

(23 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most anticancer drugs (e.g., doxorubicin, paclitaxel, curcumin, etc.) are administered intravenously, which often leads to a significant number of side effects [ 86 , 87 , 88 , 89 , 90 , 91 ]. The major limitation of present chemotherapeutic agents is the poor selectivity and the resultant toxicity [ 92 ].…”

Section: Synthetic Magnetic Nanoparticlesmentioning

confidence: 99%

Biosensors and Drug Delivery in Oncotheranostics Using Inorganic Synthetic and Biogenic Magnetic Nanoparticles

et al. 2022

View full text Add to dashboard Cite

Magnetic nanocarriers have attracted attention in translational oncology due to their ability to be employed both for tumor diagnostics and therapy. This review summarizes data on applications of synthetic and biogenic magnetic nanoparticles (MNPs) in oncological theranostics and related areas. The basics of both types of MNPs including synthesis approaches, structure, and physicochemical properties are discussed. The properties of synthetic MNPs and biogenic MNPs are compared with regard to their antitumor therapeutic efficiency, diagnostic potential, biocompatibility, and cellular toxicity. The comparative analysis demonstrates that both synthetic and biogenic MNPs could be efficiently used for cancer theranostics, including biosensorics and drug delivery. At the same time, reduced toxicity of biogenic particles was noted, which makes them advantageous for in vivo applications, such as drug delivery, or MRI imaging of tumors. Adaptability to surface modification based on natural biochemical processes is also noted, as well as good compatibility with tumor cells and proliferation in them. Advances in the bionanotechnology field should lead to the implementation of MNPs in clinical trials.

show abstract

Section: Synthetic Magnetic Nanoparticlesmentioning

confidence: 99%

Biosensors and Drug Delivery in Oncotheranostics Using Inorganic Synthetic and Biogenic Magnetic Nanoparticles

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Particularly, MSC-derived EVs may exert similar tumor-homing properties to their parental cells, as exosomes from UC-MSCs were shown to concentrate mainly in osteosarcoma tumors in vivo ( Quadri et al, 2022 ). In addition, it was demonstrated that EVs could passively reach the tumor microenvironment through enhanced permeability and retention effect ( Li H. et al, 2022 ). MSC-derived EVs also have lower immunogenicity than MSCs ( Li et al, 2021 ).…”

Section: Extracellular Vesicles As a New Paradigm For Cell-free Therapymentioning

confidence: 99%

“…For example, Wei et al reported the utilization of BM-MSC-derived EVs loaded with doxorubicin through passive co-incubation for osteosarcoma cells growth inhibition in vitro ( Wei et al, 2019 ). Drug encapsulation efficiency –the mass of drug in EVs divided by the mass of drug added to the mix - is an important parameter that has to be determined when employing co-incubation methods since these techniques often result in low loading capacity ( Villa et al, 2019 ; Li H. et al, 2022 ). In addition, it was reported that the lipid composition of the EVs may have an impact on the drug loading efficiency ( Kooijmans et al, 2021 ).…”

Section: Extracellular Vesicles As a New Paradigm For Cell-free Therapymentioning

confidence: 99%

Mesenchymal Stromal Cell-Derived Extracellular Vesicles as Biological Carriers for Drug Delivery in Cancer Therapy

Sanmartin

Borzone

Giorello

et al. 2022

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Cancer is the second leading cause of death worldwide, with 10.0 million cancer deaths in 2020. Despite advances in targeted therapies, some pharmacological drawbacks associated with anticancer chemo and immunotherapeutic agents include high toxicities, low bioavailability, and drug resistance. In recent years, extracellular vesicles emerged as a new promising platform for drug delivery, with the advantage of their inherent biocompatibility and specific targeting compared to artificial nanocarriers, such as liposomes. Particularly, mesenchymal stem/stromal cells were proposed as a source of extracellular vesicles for cancer therapy because of their intrinsic properties: high in vitro self-renewal and proliferation, regenerative and immunomodulatory capacities, and secretion of extracellular vesicles that mediate most of their paracrine functions. Moreover, extracellular vesicles are static and safer in comparison with mesenchymal stem/stromal cells, which can undergo genetic/epigenetic or phenotypic changes after their administration to patients. In this review, we summarize currently reported information regarding mesenchymal stem/stromal cell-derived extracellular vesicles, their proper isolation and purification techniques - from either naive or engineered mesenchymal stem/stromal cells - for their application in cancer therapy, as well as available downstream modification methods to improve their therapeutic properties. Additionally, we discuss the challenges associated with extracellular vesicles for cancer therapy, and we review some preclinical and clinical data available in the literature.

show abstract

“…The obtained polymeric vesicles were further cross-linked by using ethylenediamine (EDA), which endowed the membrane of the vesicles with “open” and “closed” states by adjusting the pH value. For the implementation of cell-like functions within vesicles, post-encapsulation with doxorubicin hydrochloride (DOX·HCl, an anthracycline-based broad-spectrum anticancer drug (Li et al., 2022 )), was performed without changing the morphology of the vesicles, and the in vitro release of the DOX-loaded vesicles in aqueous buffer solutions was evaluated ( Scheme 1 ). The cytotoxicity of the polymeric vesicles, free DOX and DOX-loaded vesicles to non-small cell lung carcinoma A549 cells and the intracellular drug delivery were also investigated.…”

Section: Introductionmentioning

confidence: 99%

In-depth study of anticancer drug diffusion through a cross-linked pH-responsive polymeric vesicle membrane

et al. 2023

View full text Add to dashboard Cite

Post-encapsulation and release of the anticancer drug doxorubicin hydrochloride (DOX·HCl) through cell-like transmission functions of polymeric vesicles were studied using cross-linked pH-responsive polymeric vesicles. The vesicles were fabricated for the first time via the redox-initiated reversible addition-fragmentation chain transfer dispersion polymerization in ethanol-water mixture, using 2-(diisopropylamino)ethyl methacrylate and glycidyl methacrylate, and the vesicle membrane was modified post-cross-linking by using ethylenediamine. A phase diagram was constructed for reproducible fabrication of the polymeric vesicles, and well-shaped vesicles were formed when the target degree of polymerization of the hydrophobic polymer chains was equal to or higher than 50 with solid content in the range of 10–30 wt%. The cross-linked vesicle membrane served as a gate enabling “open” and “closed” states in response to pH stimulation. Up to 50% drug loading efficiency and 39% drug loading content could be achieved, and in vitro release of the DOX-loaded vesicles in aqueous buffer solutions showed a much faster DOX release rate at pH 5.0 than at pH 6.5. The polymeric vesicles were of very low cytotoxicity to A549 cells up to the concentration of 2 mg/mL, and the IC 50 of DOX-loaded vesicles were higher than that of the free DOX. The intracellular DOX release study indicated higher cellular uptake capability for DOX-loaded vesicles than that of free DOX.

show abstract

Amplification of anticancer efficacy by co-delivery of doxorubicin and lonidamine with extracellular vesicles

Cited by 31 publications

References 50 publications

Biosensors and Drug Delivery in Oncotheranostics Using Inorganic Synthetic and Biogenic Magnetic Nanoparticles

Biosensors and Drug Delivery in Oncotheranostics Using Inorganic Synthetic and Biogenic Magnetic Nanoparticles

Mesenchymal Stromal Cell-Derived Extracellular Vesicles as Biological Carriers for Drug Delivery in Cancer Therapy

In-depth study of anticancer drug diffusion through a cross-linked pH-responsive polymeric vesicle membrane

Contact Info

Product

Resources

About

Amplification of anticancer efficacy by co-delivery of doxorubicin and lonidamine with extracellular vesicles

Cited by 31 publications

References 50 publications

Biosensors and Drug Delivery in Oncotheranostics Using Inorganic Synthetic and Biogenic Magnetic Nanoparticles

Biosensors and Drug Delivery in Oncotheranostics Using Inorganic Synthetic and Biogenic Magnetic Nanoparticles

Mesenchymal Stromal Cell-Derived Extracellular Vesicles as Biological Carriers for Drug Delivery in Cancer Therapy

In-depth study of anticancer drug diffusion through a cross-linked ­pH-responsive polymeric vesicle membrane

Contact Info

Product

Resources

About

In-depth study of anticancer drug diffusion through a cross-linked pH-responsive polymeric vesicle membrane